

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show 8 Numbers](#)[Edit 8 Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
(5 AND 3).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	5
(L3 AND L5).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	5

**Database:**

[US Patents Full-Text Database](#)  
[US Pre-Grant Publication Full-Text Database](#)  
[JPO Abstracts Database](#)  
[EPO Abstracts Database](#)  
[Derwent World Patents Index](#)  
[IBM Technical Disclosure Bulletins](#)

**Search:**

L6

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**
**DATE:** Tuesday, May 27, 2003    [Printable Copy](#)    [Create Case](#)
**Set Name   Query**  
 side by side

**Hit Count   Set Name**  
 result set

*DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; THES=ASSIGNEE;*  
*PLUR=YES; OP=AND*

<u>L6</u>	L3 and L5	5	<u>L6</u>
<u>L5</u>	(free or absence or without) same (brain adj extract)	127	<u>L5</u>
<u>L4</u>	L3 and (brain adj extract)	9	<u>L4</u>
<u>L3</u>	L2 and (VEGF and collagen)	276	<u>L3</u>
<u>L2</u>	(endothelial adj cell) same ((peripheral adj blood) or (buffy adj coat))	899	<u>L2</u>
<u>L1</u>	Hebbel-robert-P\$.in.	1	<u>L1</u>

END OF SEARCH HISTORY

```

      235 S4
S5      0 S1 AND S4
?s (EGM-2)
      S6      0 (EGM-2)
?s (EGM (w) 2)
      260 EGM
      7766646 2
      S7      12 (EGM (W) 2)
?s s1 and s7
      3353 S1
      12 S7
      S8      0 S1 AND S7
?ds

```

```

Set      Items      Description
S1      3353      (ENDOTHELIAL (W) CELL?) (S) ((PERIPHERAL (W) BLOOD) OR (BU-
      FFY (W) COAT))
S2      5      S1 AND (VEGF AND COLLAGEN)
S3      3      RD (unique items)
S4      235      (FREE OR ABSENCE OR WITHOUT) (S) (BRAIN (W) EXTRACT)
S5      0      S1 AND S4
S6      0      (EGM-2)
S7      12      (EGM (W) 2)
S8      0      S1 AND S7
?logout

```

```

27may03 16:18:20 User259876 Session D503.2
$3.17      0.992 DialUnits File155
      $0.42 2 Type(s) in Format 3
      $0.42 2 Types
$3.59 Estimated cost File155
      $5.40 0.964 DialUnits File5
      $1.75 1 Type(s) in Format 3
      $1.75 1 Types
$7.15 Estimated cost File5
      $17.37 1.877 DialUnits File73
$17.37 Estimated cost File73
      OneSearch, 3 files, 3.833 DialUnits FileOS
$1.62 TELNET
$29.73 Estimated cost this search
$30.06 Estimated total session cost 3.917 DialUnits

```

### Status: Signed Off. (7 minutes)

### Status: Path 1 of [Dialog Information Services via Modem]  
### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)  
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

\*\*\*\*\* HHHHHHHH SSSSSSSS?

### Status: Signing onto Dialog

\*\*\*\*\*

ENTER PASSWORD:

\*\*\*\*\* HHHHHHHH SSSSSSSS? \*\*\*\*\*

Password incorrect

### Status: Incorrect Account Password.

### Status: Incorrect Account Password.

### Status: Path 1 of [Dialog Information Services via Modem]

### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)  
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

\*\*\*\*\* HHHHHHHH SSSSSSSS?

### Status: Signing onto Dialog

\*\*\*\*\*

ENTER PASSWORD:

\*\*\*\*\* HHHHHHHH SSSSSSSS? \*\*\*\*\*

Welcome to DIALOG

### Status: Connected

Dialog level 02.14.01D

Last logoff: 27may03 10:09:26

Logon file001 27may03 16:12:06

KWIC is set to 50.

HIGHLIGHT set on as '\*'

\* \* \* \* See HELP NEWS 225 for information on new search prefixes  
and display codes

\*\*\*

\*\*\*

File 1:ERIC 1966-2003/May 27  
(c) format only 2003 The Dialog Corporation

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

Cost is in DialUnits

?b 155, 5, 73

27may03 16:12:17 User259876 Session D503.1

\$0.29 0.084 DialUnits File1

\$0.29 Estimated cost File1

\$0.04 TELNET

\$0.33 Estimated cost this search

\$0.33 Estimated total session cost 0.084 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2003/May W3

(c) format only 2003 The Dialog Corp.

**\*File 155: Medline has been reloaded and accession numbers have  
changed. Please see HELP NEWS 155.**

File 5:Biosis Preview(R) 1969-2003/May W3  
(c) 2003 BIOSIS

\*File 5: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 73:EMBASE 1974-2003/May W3  
(c) 2003 Elsevier Science B.V.

\*File 73: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

Set	Items	Description
---	-----	-----
?s	(endothelial (w) cell?) (s)	((peripheral (w) blood) or (buffy (w) coat))
Processing		
Processing		
	288731	ENDOTHELIAL
	7804461	CELL?
	879749	PERIPHERAL
	4591694	BLOOD
	252869	PERIPHERAL(W) BLOOD
	4802	BUFFY
	42891	COAT
	4178	BUFFY(W) COAT
S1	3353	(ENDOTHELIAL (W) CELL?) (S) ((PERIPHERAL (W) BLOOD) OR (BUFFY (W) COAT))
?s s1 and (VEGF and collagen)		
	3353	S1
	21858	VEGF
	248290	COLLAGEN
S2	5	S1 AND (VEGF AND COLLAGEN)
?rd		
...completed examining records		
S3	3	RD (unique items)
?t s3/3,k/all		

3/3,K/1 (Item 1 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2003 The Dialog Corp. All rts. reserv.

10300253 96102267 PMID: 7497521

**Suppression of \*collagen\*-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (\*VEGF\*).**

Oliver S J; Cheng T P; Banquerigo M L; Brahn E

Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA.

Cellular immunology (UNITED STATES) Dec 1995, 166 (2) p196-206,  
ISSN 0008-8749 Journal Code: 1246405

Contract/Grant No.: AR 36834; AR; NIAMS; AR 38844; AR; NIAMS; AR 40919;  
AR; NIAMS; +

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**Suppression of \*collagen\*-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (\*VEGF\*).**

Pannus formation characterized by neovascularization is a prominent pathologic finding in both rheumatoid arthritis (RA) and rat \*collagen\*-induced arthritis (CIA). CIA is a T-cell-dependent process induced by immunization of inbred LOU rats with native type II \*collagen\* in incomplete Freund's adjuvant. AGM-1470 is a highly specific inhibitor of new blood vessel formation by its effects on \*endothelial\* \*cell\* migration, \*endothelial\* \*cell\* proliferation, and capillary tube formation. Cyclosporin A (CSA) is an immunomodulating agent that inhibits IL-2 and other cytokine production involved in early antigen activation...

...type hypersensitivity responses were similar in all groups. CII antibody levels were lower in AGM-1470 protocols compared to CSA or controls. Flow cytometry of \*peripheral\* \*blood\* , spleen, and lymph nodes demonstrated decreased levels of CD4+ cells in rats given CSA. TNF-alpha levels remained elevated, even in treated rats, while vascular...

Descriptors: Arthritis, Experimental--prevention and control--PC; \*Collagen\*; \*Cyclosporine--therapeutic use--TU; \*Endothelial Growth Factors--antagonists and inhibitors--AI; \*Immunosuppressive Agents--therapeutic use--TU; \*Lymphokines--antagonists and inhibitors--AI; \*Neovascularization, Pathologic--prevention and...

Chemical Name: Endothelial Growth Factors; Immunosuppressive Agents; Lymphokines; Sesquiterpenes; Tumor Necrosis Factor; vascular endothelial growth factor; O-(chloroacetylcarbonyl)fumagillol; Cyclosporine; \*Collagen\*

3/3,K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

09338938 21097696 PMID: 11166280

**Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions.**

Schmeisser A; Garlich C D; Zhang H; Eskafi S; Graffy C; Ludwig J; Strasser R H; Daniel W G

Department of Cardiology, Technical University of Dresden, Heart Center Dresden, Fetscherstr. 76, D-01307, Dresden, Germany. alexanderschmeis@t-online.de

Cardiovascular research (Netherlands) Feb 16 2001, 49 (3) p671-80, ISSN 0008-6363 Journal Code: 0077427

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

OBJECTIVES: It has been shown that circulating human non-adherent CD34+ cells coexpressing vascular endothelial growth factor (\*VEGF\*)-R2 and AC133 have the capacity to differentiate into adherent mature \*endothelial\* \*cells\*. However, prior studies have demonstrated that a much bigger subset of primary adherent mononuclear cells can also form endothelial progenitor cells (EPC). To determine the...

... as a firmly adherent and plastic cell type have the potential to differentiate into an endothelial phenotype. METHODS: CD34-/CD14+ monocytes were isolated from human \*peripheral\* \*blood\* by adherence separation and magnetic bead selection (purity >90%) and cultured on fibronectin-coated plastic dishes (medium containing \*VEGF\* 10 ng/ml, basic fibroblast growth factor (bFGF) 2 ng/ml, insulin like growth factor (IGF-1) 1 ng/ml, 20% fetal calf serum). RESULTS...

...; AN; Biological Markers--analysis--AN; Cadherins--analysis--AN; Cell Adhesion--drug effects--DE; Cell Differentiation--drug effects--DE; Cell Division--drug effects--DE; Cells, Cultured; \*Collagen\*; Drug Combinations; Endothelial Growth Factors--pharmacology--PD; Fibroblast Growth Factor 2--pharmacology--PD; Flow Cytometry; Laminin; Lymphokines--pharmacology--PD; Monocytes--drug effects--DE; Nitric-Oxide...

...Chemical Name: Endothelial Growth Factors; Growth Substances; Laminin; Lymphokines; Proteoglycans; Receptors, Growth Factor; cadherin 5; vascular endothelial growth factor; von Willebrand Factor; Fibroblast Growth Factor 2; matrigel; \*Collagen\*; endothelial constitutive nitric oxide synthase; Nitric-Oxide Synthase; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor

3/3,K/3 (Item 1 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13557839 BIOSIS NO.: 200200186660

**Conditioned media from CLL and SLL stimulates in vitro endothelial cell proliferation and decreases endostatin generation by endothelial cells, both likely mediated by bFGF.**

AUTHOR: Rimsza Lisa M(a); Pastos Karen M(a); Lynch James W; Braylan Raul C (a)

AUTHOR ADDRESS: (a)Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL\*\*USA

JOURNAL: Blood 98 (11 Part 1):p361a November 16, 2001

MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001

ISSN: 0006-4971

RECORD TYPE: Abstract

LANGUAGE: English

**ABSTRACT:** We investigated the cellular source of increased serum basic fibroblastic growth factor (bFGF) and vascular endothelial growth factor (\*VEGF\*) reported in patients with chronic lymphocytic leukemia (CLL). We also explored the effects of tumor-secreted bFGF on \*endothelial\* \*cell\* proliferation and production of endostatin (a proteolytic fragment of \*collagen\* XVIII generated by \*endothelial\* \*cells\* from basement membrane material). We first cultured unstimulated mononuclear cells from 4 \*peripheral\* \*blood\* (PB) CLL and 5 lymph node (LN) samples of small lymphocytic lymphoma (SLL), 2 normal PB mononuclear cells, and 2 reactive LN samples. The conditioned media (CM) was assayed for secreted bFGF and \*VEGF\*, then used in a 72 hour in vitro HUVEC proliferation assay. bFGF was detected in CM from 2 of 4 PB CLL samples and 5...

...samples. HUVEC proliferation in the presence of CM was variable but proportional to secreted levels of bFGF, a correlation most pronounced in the LN samples. \*VEGF\* was not detected in CM from any of the mononuclear cell populations, although it was secreted by adherent cell layers isolated from 3 LN samples. HUVEC secreted neither \*VEGF\* nor bFGF. We next cultured HUVEC in CM from 3 CLL (1 PB, 1 pleural fluid, 1 bone marrow), 2 LN with SLL, and 1...

...may originate from the tumor cells themselves and may be responsible for increased angiogenesis in the BM and LN of these patients, while increased serum \*VEGF\* may be secreted by another cellular source such as lymph node adherent cells. Our findings also indicate that CM from human CLL and SLL samples influence endostatin generation by \*endothelial\* \*cells\*, an effect that may be mediated by bFGF. The mechanism of interaction between bFGF and endostatin might be an important direction in anti-angiogenic investigation.

**DESCRIPTORS:**

CHEMICALS & BIOCHEMICALS: ...\*collagen\* XVIII...

...vascular endothelial growth factor (\*VEGF\*)--  
?ds

Set	Items	Description
S1	3353	(ENDOTHELIAL (W) CELL?) (S) ((PERIPHERAL (W) BLOOD) OR (BU-FFY (W) COAT))
S2	5	S1 AND (VEGF AND COLLAGEN)
S3	3	RD (unique items)
?s	(free or absence or without)	(s) (brain (w) extract)
	1130217	FREE
	739147	ABSENCE
	1647695	WITHOUT
	1489463	BRAIN
	217384	EXTRACT
S4	235	(FREE OR ABSENCE OR WITHOUT) (S) (BRAIN (W) EXTRACT)
?s s1 and s4	3353	S1